Emerging agents and regimens for polycythemia vera and essential thrombocythemia
Abstract Polycythemia vera (PV) and essential thrombocythemia (ET) are both driven by JAK-STAT pathway activation and consequently much of the recent research efforts to improve the management and outcomes of patients with these neoplasms have centered around inhibition of this pathway. In addition...
Saved in:
Main Authors: | Rory M. Shallis (Author), Nikolai A. Podoltsev (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EVALUATION OF THE CORRELATION BETWEEN JAK2V617F, LEUCOCYTOSIS AND THROMBOGENIC RISK IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
by: Antonio Antonov, et al.
Published: (2018) -
Complications of neonatal polycythemia and correlation with gestational age and thrombocythemia
by: Amulya, et al.
Published: (2022) -
Polycythemia Vera (PV): Update on Emerging Treatment Options
by: Benevolo G, et al.
Published: (2021) -
Bilateral adrenal hemorrhage in polycythemia vera
by: Shruti Bhandari, et al.
Published: (2016) -
Persistent neutrophilia progressing to polycythemia vera
by: Smita Singh, et al.
Published: (2011)